Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2018, Article ID 4263520, 11 pages
https://doi.org/10.1155/2018/4263520
Research Article

Combination Therapy with EpCAM-CAR-NK-92 Cells and Regorafenib against Human Colorectal Cancer Models

1Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu 221002, China
2The Affiliated Aoyang Hospital of Jiangsu University, Zhangjiagang, Jiangsu 215600, China
3Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Xuzhou Medical University, Xuzhou, Jiangsu 221002, China

Correspondence should be addressed to Liantao Li; nc.ude.umhzx@oatnailil and Junnian Zheng; nc.ude.umhzx@gnehznj

Received 19 April 2018; Accepted 17 August 2018; Published 15 October 2018

Academic Editor: Lei Zhao

Copyright © 2018 Qing Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Arnold, M. S. Sierra, M. Laversanne, I. Soerjomataram, A. Jemal, and F. Bray, “Global patterns and trends in colorectal cancer incidence and mortality,” Gut, vol. 66, no. 4, pp. 683–691, 2017. View at Publisher · View at Google Scholar · View at Scopus
  2. T. Hu, Z. Li, C. Y. Gao, and C. H. Cho, “Mechanisms of drug resistance in colon cancer and its therapeutic strategies,” World Journal of Gastroenterology, vol. 22, no. 30, pp. 6876–6889, 2016. View at Publisher · View at Google Scholar · View at Scopus
  3. C. U. Louis, B. Savoldo, G. Dotti et al., “Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma,” Blood, vol. 118, no. 23, pp. 6050–6056, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. M. A. Pule, B. Savoldo, G. D. Myers et al., “Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma,” Nature Medicine, vol. 14, no. 11, pp. 1264–1270, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. C. E. Brown, D. Alizadeh, R. Starr et al., “Regression of glioblastoma after chimeric antigen receptor T-cell therapy,” The New England Journal of Medicine, vol. 375, no. 26, pp. 2561–2569, 2016. View at Publisher · View at Google Scholar · View at Scopus
  6. R. P. Junghans, Q. Ma, R. Rathore et al., “Phase I trial of anti-PSMA designer CAR-T cells in prostate cancer: possible role for interacting interleukin 2-T cell pharmacodynamics as a determinant of clinical response,” Prostate, vol. 76, no. 14, pp. 1257–1270, 2016. View at Publisher · View at Google Scholar · View at Scopus
  7. K. Tamada, D. Geng, Y. Sakoda et al., “Redirecting gene-modified T cells toward various cancer types using tagged antibodies,” Clinical Cancer Research, vol. 18, no. 23, pp. 6436–6445, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. C. Schlimper, A. A. Hombach, H. Abken, and I. G. H. Schmidt-Wolf, “Improved activation toward primary colorectal cancer cells by antigen-specific targeting autologous cytokine-induced killer cells,” Clinical and Developmental Immunology, vol. 2012, Article ID 238924, 8 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. T. Daly, R. E. Royal, M. H. Kershaw et al., “Recognition of human colon cancer by T cells transduced with a chimeric receptor gene,” Cancer Gene Therapy, vol. 7, no. 2, pp. 284–291, 2000. View at Publisher · View at Google Scholar · View at Scopus
  10. W. X. Ang, Z. Li, Z. Chi et al., “Intraperitoneal immunotherapy with T cells stably and transiently expressing anti-EpCAM CAR in xenograft models of peritoneal carcinomatosis,” Oncotarget, vol. 8, no. 8, pp. 13545–13559, 2017. View at Publisher · View at Google Scholar · View at Scopus
  11. R. A. Morgan, J. C. Yang, M. Kitano, M. E. Dudley, C. M. Laurencot, and S. A. Rosenberg, “Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2,” Molecular Therapy, vol. 18, no. 4, pp. 843–851, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. K. M. Hege, E. K. Bergsland, G. A. Fisher et al., “Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer,” Journal for ImmunoTherapy of Cancer, vol. 5, no. 1, p. 22, 2017. View at Publisher · View at Google Scholar · View at Scopus
  13. C. Zhang, Z. Wang, Z. Yang et al., “Phase I escalating-dose trial of CAR-T therapy targeting CEA+ metastatic colorectal cancers,” Molecular Therapy, vol. 25, no. 5, pp. 1248–1258, 2017. View at Publisher · View at Google Scholar · View at Scopus
  14. F. C. Thistlethwaite, D. E. Gilham, R. D. Guest et al., “The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity,” Cancer Immunology, Immunotherapy, vol. 66, no. 11, pp. 1425–1436, 2017. View at Publisher · View at Google Scholar · View at Scopus
  15. Y. Li, Y. Duo, S. Bao et al., “EpCAM aptamer-functionalized polydopamine-coated mesoporous silica nanoparticles loaded with DM1 for targeted therapy in colorectal cancer,” International Journal of Nanomedicine, vol. 12, pp. 6239–6257, 2017. View at Publisher · View at Google Scholar · View at Scopus
  16. H. Hao, Y. Zhen, Z. Wang, F. Chen, and X. Xie, “A novel therapeutic drug for colon cancer: EpCAM scFv-truncated protamine (tp)-siRNA,” Cell Biology International, vol. 37, no. 8, pp. 860–864, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Y. Liao, J. K. Lai, M. Y. Kuo et al., “An anti-EpCAM antibody EpAb2-6 for the treatment of colon cancer,” Oncotarget, vol. 6, no. 28, pp. 24947–24968, 2015. View at Publisher · View at Google Scholar · View at Scopus
  18. G. Pietra, C. Vitale, D. Pende et al., “Human natural killer cells: news in the therapy of solid tumors and high-risk leukemias,” Cancer Immunology, Immunotherapy, vol. 65, no. 4, pp. 465–476, 2016. View at Publisher · View at Google Scholar · View at Scopus
  19. J. H. Gong, G. Maki, and H. G. Klingemann, “Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells,” Leukemia, vol. 8, no. 4, pp. 652–658, 1994. View at Google Scholar
  20. M. A. Geller and J. S. Miller, “Use of allogeneic NK cells for cancer immunotherapy,” Immunotherapy, vol. 3, no. 12, pp. 1445–1459, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Arai, R. Meagher, M. Swearingen et al., “Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial,” Cytotherapy, vol. 10, no. 6, pp. 625–632, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. Q. Zhang, K. Tian, J. Xu et al., “Synergistic effects of cabozantinib and EGFR-specific CAR-NK-92 cells in renal cell carcinoma,” Journal of Immunology Research, vol. 2017, Article ID 6915912, 14 pages, 2017. View at Publisher · View at Google Scholar · View at Scopus
  23. D. H. Munn, M. D. Sharma, T. S. Johnson, and P. Rodriguez, “IDO, PTEN-expressing Tregs and control of antigen-presentation in the murine tumor microenvironment,” Cancer Immunology, Immunotherapy, vol. 66, no. 8, pp. 1049–1058, 2017. View at Publisher · View at Google Scholar · View at Scopus
  24. K. K. Goswami, T. Ghosh, S. Ghosh, M. Sarkar, A. Bose, and R. Baral, “Tumor promoting role of anti-tumor macrophages in tumor microenvironment,” Cellular Immunology, vol. 316, pp. 1–10, 2017. View at Publisher · View at Google Scholar · View at Scopus
  25. I. Scarfo and M. V. Maus, “Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment,” Journal for ImmunoTherapy of Cancer, vol. 5, no. 1, p. 28, 2017. View at Publisher · View at Google Scholar · View at Scopus
  26. J. Xu, K. Tian, H. Zhang et al., “Chimeric antigen receptor-T cell therapy for solid tumors require new clinical regimens,” Expert Review of Anticancer Therapy, vol. 17, no. 12, pp. 1099–1106, 2017. View at Publisher · View at Google Scholar · View at Scopus
  27. H. Huynh, R. Ong, and D. Zopf, “Antitumor activity of the multikinase inhibitor regorafenib in patient-derived xenograft models of gastric cancer,” Journal of Experimental & Clinical Cancer Research, vol. 34, no. 1, p. 132, 2015. View at Publisher · View at Google Scholar · View at Scopus
  28. H. Takigawa, Y. Kitadai, K. Shinagawa et al., “Multikinase inhibitor regorafenib inhibits the growth and metastasis of colon cancer with abundant stroma,” Cancer Science, vol. 107, no. 5, pp. 601–608, 2016. View at Publisher · View at Google Scholar · View at Scopus
  29. J. Hu, S. Zhu, X. Xia, L. Zhang, E. S. Kleinerman, and S. Li, “CD8+T cell-specific induction of NKG2D receptor by doxorubicin plus interleukin-12 and its contribution to CD8+T cell accumulation in tumors,” Molecular Cancer, vol. 13, no. 1, p. 34, 2014. View at Publisher · View at Google Scholar · View at Scopus
  30. D. Alizadeh, M. Trad, N. T. Hanke et al., “Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer,” Cancer Research, vol. 74, no. 1, pp. 104–118, 2014. View at Publisher · View at Google Scholar · View at Scopus
  31. J. S. Ko, A. H. Zea, B. I. Rini et al., “Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients,” Clinical Cancer Research, vol. 15, no. 6, pp. 2148–2157, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. J. H. Finke, B. Rini, J. Ireland et al., “Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients,” Clinical Cancer Research, vol. 14, no. 20, pp. 6674–6682, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. A. Busse, A. M. Asemissen, A. Nonnenmacher et al., “Immunomodulatory effects of sorafenib on peripheral immune effector cells in metastatic renal cell carcinoma,” European Journal of Cancer, vol. 47, no. 5, pp. 690–696, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. R. Cabrera, M. Ararat, Y. Xu et al., “Immune modulation of effector CD4+ and regulatory T cell function by sorafenib in patients with hepatocellular carcinoma,” Cancer Immunology, Immunotherapy, vol. 62, no. 4, pp. 737–746, 2013. View at Publisher · View at Google Scholar · View at Scopus
  35. E. Suzuki, V. Kapoor, A. S. Jassar, L. R. Kaiser, and S. M. Albelda, “Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity,” Clinical Cancer Research, vol. 11, no. 18, pp. 6713–6721, 2005. View at Publisher · View at Google Scholar · View at Scopus
  36. S. K. Bunt, A. M. Mohr, J. M. Bailey, P. M. Grandgenett, and M. A. Hollingsworth, “Rosiglitazone and gemcitabine in combination reduces immune suppression and modulates T cell populations in pancreatic cancer,” Cancer Immunology, Immunotherapy, vol. 62, no. 2, pp. 225–236, 2013. View at Publisher · View at Google Scholar · View at Scopus
  37. Y. Homma, K. Taniguchi, M. Nakazawa et al., “Changes in the immune cell population and cell proliferation in peripheral blood after gemcitabine-based chemotherapy for pancreatic cancer,” Clinical & Translational Oncology, vol. 16, no. 3, pp. 330–335, 2014. View at Publisher · View at Google Scholar · View at Scopus
  38. F. T. Hsu, T. C. Chen, H. Y. Chuang, Y. F. Chang, and J. J. Hwang, “Enhancement of adoptive T cell transfer with single low dose pretreatment of doxorubicin or paclitaxel in mice,” Oncotarget, vol. 6, no. 42, pp. 44134–44150, 2015. View at Publisher · View at Google Scholar · View at Scopus
  39. H. Matsushita, Y. Enomoto, H. Kume et al., “A pilot study of autologous tumor lysate-loaded dendritic cell vaccination combined with sunitinib for metastatic renal cell carcinoma,” Journal for ImmunoTherapy of Cancer, vol. 2, no. 1, p. 30, 2014. View at Publisher · View at Google Scholar · View at Scopus
  40. A. Takahara, S. Koido, M. Ito et al., “Gemcitabine enhances Wilms’ tumor gene WT1 expression and sensitizes human pancreatic cancer cells with WT1-specific T-cell-mediated antitumor immune response,” Cancer Immunology, Immunotherapy, vol. 60, no. 9, pp. 1289–1297, 2011. View at Publisher · View at Google Scholar · View at Scopus
  41. E. Daudigeos-Dubus, L. le Dret, C. Lanvers-Kaminsky et al., “Regorafenib: antitumor activity upon mono and combination therapy in preclinical pediatric malignancy models,” PLoS One, vol. 10, no. 11, article e0142612, 2015. View at Publisher · View at Google Scholar · View at Scopus
  42. Y. Wu, Z. Deng, Y. Tang, S. Zhang, and Y. Q. Zhang, “Over-expressing Akt in T cells to resist tumor immunosuppression and increase anti-tumor activity,” BMC Cancer, vol. 15, no. 1, p. 603, 2015. View at Publisher · View at Google Scholar · View at Scopus
  43. N. Shirasu, H. Yamada, H. Shibaguchi, M. Kuroki, and M. Kuroki, “Molecular characterization of a fully human chimeric T-cell antigen receptor for tumor-associated antigen EpCAM,” Journal of Biomedicine and Biotechnology, vol. 2012, Article ID 853879, 7 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  44. Z. Deng, Y. Wu, W. Ma, S. Zhang, and Y. Q. Zhang, “Adoptive T-cell therapy of prostate cancer targeting the cancer stem cell antigen EpCAM,” BMC Immunology, vol. 16, no. 1, p. 1, 2015. View at Publisher · View at Google Scholar · View at Scopus
  45. C. Sahm, K. Schonfeld, and W. S. Wels, “Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor,” Cancer Immunology, Immunotherapy, vol. 61, no. 9, pp. 1451–1461, 2012. View at Publisher · View at Google Scholar · View at Scopus
  46. R. Meier, D. Golovko, S. Tavri et al., “Depicting adoptive immunotherapy for prostate cancer in an animal model with magnetic resonance imaging,” Magnetic Resonance in Medicine, vol. 65, no. 3, pp. 756–763, 2011. View at Publisher · View at Google Scholar · View at Scopus
  47. B. Melosky, “Meeting an unmet need in metastatic colorectal carcinoma with regorafenib,” Asia-Pacific Journal of Oncology Nursing, vol. 3, no. 1, pp. 58–65, 2016. View at Publisher · View at Google Scholar
  48. A. Sacré, N. Lanthier, H. Dano et al., “Regorafenib induced severe toxic hepatitis: characterization and discussion,” Liver International, vol. 36, no. 11, pp. 1590–1594, 2016. View at Publisher · View at Google Scholar · View at Scopus
  49. J. Ozao-Choy, G. Ma, J. Kao et al., “The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies,” Cancer Research, vol. 69, no. 6, pp. 2514–2522, 2009. View at Publisher · View at Google Scholar · View at Scopus
  50. A. Patnaik, K. D. Swanson, E. Csizmadia et al., “Cabozantinib eradicates advanced murine prostate cancer by activating antitumor innate immunity,” Cancer Discovery, vol. 7, no. 7, pp. 750–765, 2017. View at Publisher · View at Google Scholar · View at Scopus